z-logo
open-access-imgOpen Access
THE EFFECT OF SOLID LIPID NANOPARTICLES ON TAMOXIFEN-RESISTANT BREAST CANCER CELLS
Author(s) -
Gamze Güney Eskiler,
Gülşah Çeçener,
Gökhan Dıkmen,
Lütfı Genç,
Ünal Egelí
Publication year - 2016
Publication title -
international journal of pharmacy and pharmaceutical sciences
Language(s) - English
Resource type - Journals
eISSN - 2656-0097
pISSN - 0975-1491
DOI - 10.22159/ijpps.2016v8s2.15220
Subject(s) - solid lipid nanoparticle , tamoxifen , viability assay , cytotoxicity , apoptosis , cytotoxic t cell , cancer cell , cancer research , breast cancer , in vitro , pharmacology , chemistry , medicine , cancer , drug , biochemistry
To overcome the acquired Tamoxifen (Tam) resistance in Tam-resistant breast cancer cells without damaging normal cells, we have examined the therapeutic efficacy of Tam-loaded solid lipid nanoparticles (SLNs). Tam-loaded SLNs were produced by hot homogenization method. After characterization, in vitro cytotoxic and apoptotic activity of Tam-SLNs were evaluated in MCF7, MCF7-TamR (Tam-resistant breast cancer cells) and MCF10A cells. Tam-SLNs had an average size nearly 300 nm and a zeta potential of approximately-40 mV. In vitro cytotoxicity results showed that Tam-SLNs indicated the cytotoxic and apoptotic activity on MCF7 and MCF7-TamR cells. We found that MCF7-TamR cell viability was also suppressed significantly by Tam-SLNs and thus, Tam-SLNs could delay and overcome Tam-resistance (p<0.05). Furthermore, the Tam-SLNs did not induce apoptosis on MCF10A control cells. The lowest MCF10A cell viability was 83.0% whereas MCF7 and MCF7-TamR (R↔ and R↑) cells viability are reduced to 21.98%, 27.5% and 29.4% at 10 µM of Tam-SLNs, respectively (p<0.05). The obtained results were supported by apoptosis assays. SLNs-delivery system provided therapeutic efficacy to overcome Tam-resistance thanks to unique features of SLNs including small size, drug accumulation in the tumor site and controlled drug release. Therefore, Tam-SLNs may have therapeutic potential for the treatment of TAM-resistant breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom